Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

CRESCENT BIOPHARMA, INC.

CBIO · Nasdaq · CIK 0001253689 · Healthcare · Biotechnology

INSIDER SIGNAL

60.9 / 100

1 buyers · 1 purchase transaction lines · $12.4M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeStrong
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+23.1 / 25
Role+20.0 / 20
Recency+2.0 / 10
Conviction+8.8 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director,TenPercentOwner

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas · $12.4M
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-07-16–2026-07-16

Roles in the peak window: Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
McNeill JonathanPresident and COO
▼▼▼
Brumm Joshua TChief Executive Officer
▼▼▼
Scalzo Richard WilliamChief Financial Officer
▼▼
Pinkas JanChief Scientific Officer
▼▼
Lynch RyanSee Remarks
▼▼
Im Ellie EunkyungChief Medical Officer
▼▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

SIGNAL HISTORY

60.9 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 61.0
  2. 60.9
  3. 60.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
16Sales
16Other Form 4 lines
24SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING16 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,777,172
Previous report
3,407,158
Avg daily volume
697,402
Days to cover
6.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-16Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasPurchase (P)Ordinary Shares853,450USD 14.50USD 12,375,025SEC filing ↗
2025-12-04Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasPurchase (P)Ordinary Shares1,360,000USD 13.41USD 18,237,600SEC filing ↗
2024-06-21Rock EdwinPurchase (P)Common Stock115,000USD 0.27USD 31,050SEC filing ↗
2024-06-20Rock EdwinPurchase (P)Common Stock190,000USD 0.25USD 47,500SEC filing ↗
2024-06-18Hahn Brian M.Purchase (P)Common Stock17,500USD 0.25USD 4,375SEC filing ↗
2023-09-22Rock EdwinPurchase (P)Common Stock30,403USD 1.38USD 41,956SEC filing ↗
2023-09-21Rock EdwinPurchase (P)Common Stock35,000USD 1.38USD 48,300SEC filing ↗
2023-05-10JUNIUS DANIEL MPurchase (P)Common Stock30,000USD 1.56USD 46,800SEC filing ↗
2023-05-08Johnson Bruce SPurchase (P)Common Stock13,500USD 1.57USD 21,195SEC filing ↗
2023-02-24Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck AmauryPurchase (P)Common Stock100,000USD 1.70USD 170,000SEC filing ↗
2023-02-23Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck AmauryPurchase (P)Common Stock200,000USD 1.75USD 350,000SEC filing ↗
2023-02-22Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck AmauryPurchase (P)Common Stock150,000USD 1.79USD 268,500SEC filing ↗
2023-02-21Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck AmauryPurchase (P)Common Stock50,000USD 1.85USD 92,500SEC filing ↗
2023-02-17Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck AmauryPurchase (P)Common Stock200,000USD 1.71USD 342,000SEC filing ↗
2023-02-16Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck AmauryPurchase (P)Common Stock315,266USD 1.68USD 529,647SEC filing ↗

Form 4 evidence

34 transaction lines in the latest 365-day window; 122 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-18McNeill JonathanSale (S)Ordinary Shares3,839USD 16.71USD 64,150SEC filing ↗
2026-09-18Brumm Joshua TSale (S)Ordinary Shares7,837USD 16.71USD 130,956SEC filing ↗
2026-09-16Scalzo Richard WilliamSale (S)Ordinary Shares568USD 17.90USD 10,167SEC filing ↗
Show recent Form 4 evidence (26 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-18McNeill JonathanSale (S)Ordinary Shares3,839USD 16.71USD 64,150SEC filing ↗
2026-09-18Brumm Joshua TSale (S)Ordinary Shares7,837USD 16.71USD 130,956SEC filing ↗
2026-09-16Scalzo Richard WilliamSale (S)Ordinary Shares568USD 17.90USD 10,167SEC filing ↗
2026-09-16Pinkas JanSale (S)Ordinary Shares658USD 17.90USD 11,778SEC filing ↗
2026-09-16McNeill JonathanSale (S)Ordinary Shares731USD 17.90USD 13,085SEC filing ↗
2026-09-16Lynch RyanSale (S)Ordinary Shares240USD 17.90USD 4,296SEC filing ↗
2026-09-16Im Ellie EunkyungSale (S)Ordinary Shares623USD 17.90USD 11,152SEC filing ↗
2026-09-16Brumm Joshua TSale (S)Ordinary Shares1,610USD 17.90USD 28,819SEC filing ↗
2026-09-16Bispham Barbara HarlinSale (S)Ordinary Shares620USD 17.90USD 11,098SEC filing ↗
2026-07-16Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasPurchase (P)Ordinary Shares853,450USD 14.50USD 12,375,025SEC filing ↗
2026-06-22Scalzo Richard WilliamSale (S)Ordinary Shares1,112USD 17.99USD 20,005SEC filing ↗
2026-06-22Pinkas JanSale (S)Ordinary Shares1,288USD 17.99USD 23,171SEC filing ↗
2026-06-22McNeill JonathanSale (S)Ordinary Shares20,549USD 17.99USD 369,677SEC filing ↗
2026-06-22Lynch RyanSale (S)Ordinary Shares465USD 17.99USD 8,365SEC filing ↗
2026-06-22Im Ellie EunkyungSale (S)Ordinary Shares1,219USD 17.99USD 21,930SEC filing ↗
2026-06-22Brumm Joshua TSale (S)Ordinary Shares42,305USD 17.99USD 761,067SEC filing ↗
2026-06-22Bispham Barbara HarlinSale (S)Ordinary Shares1,218USD 17.99USD 21,912SEC filing ↗
2025-12-15Scalzo Richard WilliamAward / grant (A)Ordinary Shares19,422USD —USD —SEC filing ↗
2025-12-15Pinkas JanAward / grant (A)Ordinary Shares22,507USD —USD —SEC filing ↗
2025-12-15McNeill JonathanAward / grant (A)Ordinary Shares25,507USD —USD —SEC filing ↗
2025-12-15Lynch RyanAward / grant (A)Ordinary Shares12,378USD —USD —SEC filing ↗
2025-12-15Im Ellie EunkyungAward / grant (A)Ordinary Shares21,298USD —USD —SEC filing ↗
2025-12-15Doughty Christopher GrantAward / grant (A)Ordinary Shares22,714USD —USD —SEC filing ↗
2025-12-15Brumm Joshua TAward / grant (A)Ordinary Shares55,117USD —USD —SEC filing ↗
2025-12-15Bispham Barbara HarlinAward / grant (A)Ordinary Shares18,422USD —USD —SEC filing ↗
2025-12-04Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasPurchase (P)Ordinary Shares1,360,000USD 13.41USD 18,237,600SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCBIO
CIK0001253689
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history122 transaction lines from 2020-01-06 to 2026-09-18
34 P purchase lines · 42 S sale lines · 46 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.